The proposal to block the routine NHS use of two drugs for advanced bowel cancer has raised questions about how expensive drugs can be funded and whether there is a role for critical illness cover in this area.
The National Institute for Health and Clinical Excellence (NICE) has stated there is insufficient evidence to recommend the bowel cancer drugs – called Avastin and Erbitux – and it is therefore proposing to block their routine use by the NHS. Charities are arguing the drugs have been shown to extend life expectancy by four to five months in some patients. Under the NICE proposal, a patient may be issued the drugs if they can show they are an “exceptional case”, but it is unclear what “exceptional” means and it is unlikely those patients falling outside the definition will be able to fun...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes